Collaboration and Licensing Revenue (Tables)

3 Months Ended

Mar. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three months ended March 31, 2018 and 2017.

	Three Months Ended   March 31,
	2018 (As Restated)		2017
ZIOPHARM Oncology, Inc.	$	5,377	$	10,985
Oragenics, Inc.	125		569
Fibrocell Science, Inc.	293		1,739
Genopaver, LLC	1,315		1,680
S & I Ophthalmic, LLC	—		303
OvaXon, LLC	—		824
Intrexon Energy Partners, LLC	1,197		5,086
Persea Bio, LLC	209		289
Ares Trading S.A.	2,423		3,315
Intrexon Energy Partners II, LLC	378		1,149
Intrexon T1D Partners, LLC	1,328		1,132
Harvest start-up entities (1)	3,197		3,363
Other	4,006		2,631
Total	$	19,848	$	33,065

(1) For the three months ended March 31, 2018 and 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc. For the three months ended March 31, 2017, revenue recognized from collaborations with Harvest start-up entities also includes Relieve Genetics, Inc.

Summary of Deferred Revenue

Deferred revenue consists of the following:

	March 31, 2018 (As Restated)		December 31, 2017
Collaboration and licensing agreements	$	195,478	$	231,583
Prepaid product and service revenues	5,138		4,681
Other	78		133
Total	$	200,694	$	236,397
Current portion of deferred revenue	$	38,376	$	42,870
Long-term portion of deferred revenue	162,318		193,527
Total	$	200,694	$	236,397

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement as of March 31, 2018 and December 31, 2017, including the estimated remaining performance period as of March 31, 2018.

	Average Remaining Performance Period (Years)	March 31, 2018 (As Restated)		December 31, 2017
ZIOPHARM Oncology, Inc.	5.8	$	55,210	$	90,496
Oragenics, Inc.	6.2	6,819		6,719
Fibrocell Science, Inc.	6.6	18,258		16,607
Genopaver, LLC	6.0	1,468		1,704
Intrexon Energy Partners, LLC	6.0	14,184		15,625
Persea Bio, LLC	6.8	3,046		3,500
Ares Trading S.A.	6.1	39,699		40,789
Intrexon Energy Partners II, LLC	6.7	15,552		13,833
Intrexon T1D Partners, LLC	7.0	9,665		8,435
Harvest start-up entities (1)	7.1	19,162		18,400
Other	3.7	11,537		14,423
Total		$	194,600	$	230,531

(1) As of March 31, 2018 and December 31, 2017, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.